%0 Journal Article
%A Platen, Moritz
%A Gläser, Eva
%A Dahling, Volker
%A Gesell, Daniela
%A Hauptmann, Michael
%A Horenkamp-Sonntag, Dirk
%A Koller, Daniela
%A Kubat, Denise
%A Marschall, Ursula
%A Riederer, Cordula
%A Scheibner, Hannah
%A Schroth, Jennifer
%A Swart, Enno
%A Michalowsky, Bernhard
%T Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer's therapies.
%J Alzheimer's research & therapy
%V 17
%N 1
%@ 1758-9193
%C London
%I BioMed Central
%M DZNE-2025-01365
%P 259
%D 2025
%X Current antidementia drugs can temporarily slow cognitive decline in Alzheimer's disease but are underused. Regional and socioeconomic disparities, including limited specialist access in rural or deprived areas, may exacerbate inequities and challenge the rollout of emerging disease-modifying therapies. This study aimed to evaluate associations between regional contextual factors and antidementia drug prescription (AD-Rx) among newly diagnosed people living with Alzheimer's disease (PlwAD) in Germany and to identify spatial clustering of prescribing patterns.This study analyzed anonymized claims data from three statutory health insurers for 53,753 PlwAD who received their first diagnosis between January 2020 and December 2022. Regions, defined by three-digit postal codes (ZIP3, n = 576), were categorized by the German Index of Socioeconomic Deprivation (GISD) quintiles and Degree of Urbanization (urban, suburban, rural). Multilevel logistic regression with random intercepts for ZIP3 was used to assess associations between receiving AD-Rx (dichotomous) and urbanization and deprivation, adjusting for age, sex, the Charlson Comorbidity Index, the long-term care level and the year of diagnosis. Global Moran's I was used to evaluate large-scale spatial clustering, and regional Moran's I was calculated to detect regional hotspots and coldspots.Overall, 64
%K Humans
%K Germany: epidemiology
%K Alzheimer Disease: drug therapy
%K Alzheimer Disease: epidemiology
%K Male
%K Female
%K Aged
%K Healthcare Disparities: statistics & numerical data
%K Aged, 80 and over
%K Rural Population
%K Nootropic Agents: therapeutic use
%K Socioeconomic Factors
%K Middle Aged
%K Alzheimer’s disease (Other)
%K Antidementia drug treatment (Other)
%K Deprivation (Other)
%K Disease-modifying treatments, geographical variation, spatial analysis (Other)
%K Healthcare disparities (Other)
%K Real-world data (Other)
%K Real-world evidence (Other)
%K Rural population (Other)
%K Nootropic Agents (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41345718
%2 pmc:PMC12696915
%R 10.1186/s13195-025-01902-8
%U https://pub.dzne.de/record/282629